LILRB1 and neoplasm: The post-CT sHLA-G status (<16.35> ng/ml), the ILT-2 rs10416697C carrier status, the pre-CT nodal status (pN- vs. pN+), the menopausal status (premeno/peri vs. postmenopausal), the age (<60>), post-CT tumor size (T1>), and the pathological response of therapy (pCR vs. pPR/NR) were subjected as co-variates to the multivariate analysis for PFS and OS.